CDK4 is an inclusion criterion in 2 clinical trials for liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [4].

Palbociclib has evidence of efficacy in patients with CDK4 mutation in liposarcoma [4].

CDK4 is an inclusion criterion in 12 clinical trials for malignant solid tumor, of which 11 are open and 1 is closed. Of the trials that contain CDK4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 10 are phase 2 (9 open) [4].

CDK4 is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 2 are open and 2 are closed. Of the trials that contain CDK4 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDK4 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain CDK4 status and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) [4].

CDK4 is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain CDK4 status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [4].

CDK4 is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 3 are open and 0 are closed. Of the trials that contain CDK4 status and soft tissue sarcoma as inclusion criteria, 3 are phase 2 (3 open) [4].

CDK4 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK4 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK4 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK4 is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and osteosarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK4 is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and ovarian carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and acral lentiginous melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CDK4 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and chordoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK4 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK4 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDK4 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and leiomyosarcoma as inclusion criteria, 1 is phase 3 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK4 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [4].